Migren Tedavisi İçin Nanoteknoloji Temelli İlaç Uygulamaları
Özet
Dünya nüfusunun %15-18'ini etkileyen ve engelliliğin önde gelen nedenlerinden biri olan migrenin tedavisinde nanoteknoloji temelli ilaç taşıyıcı sistemlerin potansiyeli büyük önem taşımaktadır. Geleneksel migren ilaçlarının düşük emilim, kısa yarı ömür ve yan etkiler gibi kısıtlamaları, bilim insanlarını daha spesifik ve yüksek biyoyararlanımlı yeni teknolojiler geliştirmeye yöneltmiştir. Son yıllarda 5-HT1F reseptör agonistleri, CGRP reseptör antagonistleri ve monoklonal antikorlar gibi yeni tedavi yöntemleri öne çıkmıştır. Ancak, santral sinir sistemi hastalıklarının tedavisinde kan-beyin bariyeri (KBB) önemli bir engel oluşturmaktadır. Nanoteknoloji, ilaçların bu bariyeri geçmesini sağlayarak hedef dokuya sürekli ve daha güvenli bir şekilde iletilmesine imkan tanımaktadır. İncelemede polimerik nanopartiküller, katı lipid nanopartikülleri, nanoemülsiyonlar, polimerik miseller ve demir oksit nanopartikülleri gibi farklı taşıyıcı sistemler ele alınmıştır. Yapılan hayvan çalışmalarında, zolmitriptan, nistatin, sumatriptan ve rizatriptan yüklü nanoformülasyonların beyindeki ilaç konsantrasyonunu ve anti-migren etkinliğini saf ilaçlara kıyasla anlamlı derecede artırdığı gösterilmiştir. Sonuç olarak, bu sistemlerin gelecekte insan klinik çalışmalarında da başarı göstermesiyle günlük hayata entegre olması ve migrenin yarattığı sosyo-ekonomik yükü büyük ölçüde azaltması beklenmektedir.
The potential of nanotechnology-based drug delivery systems carries great importance in the treatment of migraine, which affects 15-18% of the global population and stands as a leading cause of disability. The limitations of conventional migraine medications, such as low absorption, short half-life, and adverse effects, have led scientists to develop new technologies with higher bioavailability and specificity. Recently, novel therapeutic approaches like 5-HT1F receptor agonists, CGRP receptor antagonists, and monoclonal antibodies have emerged. However, the blood-brain barrier (BBB) poses a significant obstacle in treating central nervous system disorders. Nanotechnology addresses this challenge by enabling drugs to cross this barrier, allowing sustained and safer delivery to the target tissue. The review covers various carrier systems, including polymeric nanoparticles, solid lipid nanoparticles, nanoemulsions, polymeric micelles, and iron oxide nanoparticles. Animal studies have demonstrated that nanoformulations loaded with zolmitriptan, nystatin, sumatriptan, and rizatriptan significantly increase drug concentration in the brain and enhance anti-migraine efficacy compared to pure drugs. Consequently, upon succeeding in future human clinical trials, these systems are highly anticipated to integrate into daily life and substantially alleviate the socio-economic burden of migraine.
Referanslar
Silberstein SD. Migrain , Lancet, 2004,Jan 31;363(9406):381-91. Doi: 10.1016/S0140-6736(04)15440-8
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 25.2 Suppl 2019; S23-S34.
Srikanth M, Kessler JA. Nanotechnology—novel therapeutics for CNS disorders. Nature Reviews Neurology, 2012; 8.6: 307-318. Doi:10.1038/nrneurol.2012.76
Güven E. Nanotechnology-based drug delivery systems in orthopedics. Joint Diseases and Related Surgery, 2021; 32.1: 267. Doi: 10.5606/ehc.2021.80360
Ashina M. Migraine, N Engl J Med 383 2020; 1866-76. Doi:10.1056/nejmra1915327
Stovner LJ, Nichols E, Steiner TJ et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 2018; 17.11: 954-976. Doi:10.1016/s1474-4422(18)30322-3
Çopur T, Bozdağ Pehlivan S, Öner L. Migren Tedavisinde Nanoteknoloji Temelli İlaç Taşıyıcı Sistemler. Hacettepe University Journal of the Faculty of Pharmacy, 2021; 41.1: 23-34.
Agosti Reto M. 5HT1F-and 5HT7-receptor agonists for the treatment of migraines. CNS & Neurological Disorders-Drug Targets. Formerly Current Drug Targets-CNS & Neurological Disorders, 2007; 6.4: 235-237. Doi: 10.2174/187152707781387242
Goldstein DJ, Roon KI, Offen WW et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial Lancet. 2001; 358, 1230-4.
Lambru G, Andreou AP, Guglielmetti M, et al. Emerging drugs for migraine treatment: an update. Expert opinion on emerging drugs. 2018; 23.4: 301-318. Doi: 10.1080/14728214.2018.1552939
Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene—related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104–1110.
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123.
Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83:958–966.
Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304–1312.
Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712–722
Diener HC, Barbanti P, Dahlöf C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573–584.
Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114–125 Doi: 10.1177/033310241350727
Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase III randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037
Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088. Doi: 10.1001/jamaneurol.2018.1212
Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454 Doi: 10.1177/0333102418779543
Caronna E, Starling AJ. Update on calcitonin gene-related peptide antagonism in the treatment of migraine. Neurologic clinics 2021; 39.1: 1-19.
Edvinsson L. PACAP and its receptors in migraine pathophysiology: commentary on Walker et al. Br J Pharmacol 171: 1521-1533. Br J Pharmacol. 2015;172(19):4782–4784. Doi: 10.1111/bph.12772
Edvinsson L, Tajti J, Szalardy L, et al. PACAP and its role in primary headaches. J Headache Pain. 2018;19(1):21. Doi: 10.1186/s10194-018-0852-4
Ahlawat J, Henriquez G, Narayan M. Enhancing the delivery of chemotherapeutics: role of biodegradable polymeric nanoparticles. Molecules, 2018, 23.9: 2157. Doi: 10.3390/moleküller23092157
Khezri F, Lakshmi CSR, Bukka R, et al. Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method.International Journal of Biological Macromolecules 2020,142: 52-62. Doi:10.1016/j.ijbiomac.2019.08.236
Girotra P, Thakur A, Kumar A, et al. Identification of multi-targeted anti-migraine potential of nystatin and development of its brain targeted chitosan nanoformulation. International Journal of Biological Macromolecules 2017, 96: 687-696. Doi: 10.1016/j.ijbiomac.2016.12.065
Esim O, Savaser A, Kurbanoglu S, et al: Development of assay for determination of eletriptan hydrobromide in loaded PLGA nanoparticles.Journal of Pharmaceutical and Biomedical Analysis 2017; 142: 74-83. Doi: 10.1016/j.jpba.2017.05.002
Girotra P, Singh SK. A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.Pharmaceutical Research 2016; 33(7): 1682-1695. Doi: 10.1007/s11095-016-1910-8
Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: Pharmacological and biopharmaceutical aspects. Frontiers in Molecular Biosciences, 2020; 7: 319. Doi:10.3389/fmolb.2020.587997
Hansraj GP, Singh SK, Kumar P. Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential. International journal of biological macromolecules, 2015; 81: 467-476. Doi:10.1016/j.ijbiomac.2015.08.035
Girotra P, Singh SK. Multivariate optimization of rizatriptan benzoate-loaded solid lipid nanoparticles for brain targeting and migraine management. AAPS PharmSciTech, 2017; 18.2: 517-528. Doi: 10.1208/s12249-016-0532-0
Youssef NAHA, Kassem AA, Farid RG, et al. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. International Journal of Pharmaceutics 2018; 548(1):609-624. Doi: 10.1016/j.ijpharm.2018.07.014
İlyasoğlu H, El SN. Nanoemülsiyonlar: Oluşumları, yapıları ve kollodial salınım sistemleri olarak gıda sektöründe kullanım alanları. Gıda, 2010; 35.2: 143-150.
Bhanushalı RS, Gatne MM, Gaikwad RV et al. Nanoemulsion based intranasal delivery of antimigraine drugs for nose to brain targeting. Indian Journal of Pharmaceutical Sciences, 2009; 71.6: 707.
Jain R, Nabar S, Dandekar P, et al. Micellar Nanocarriers: Potential Nose-to-Brain Delivery of Zolmitriptan as Novel Migraine Therapy. Pharmaceutical Research 2010; 27(4):655-664 Doi: 10.1007/s11095-009-0041-x
Berah R, Ghorbani M, Moghadamnia AA. Synthesis of a smart pH-responsive magnetic nanocomposite as high loading carrier of pharmaceutical agents. International Journal of Biological Macromolecules. 2017; 99: 731-738 Doi: 10.1016/j.ijbiomac.2017.03.039
